Michael Ferguson
Director/Board Member at NANOVIBRONIX, INC.
Net worth: - $ as of 2024-05-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Harold Jacob | M | 69 | 21 years | |
| Ira Greenstein | M | 63 | 10 years | |
| Stephen Brown | M | 67 | 9 years | |
| Brian Murphy | M | 67 | 8 years | |
| Franco Cassar | M | 63 | 2 years | |
| Martin Goldstein | M | 56 | 9 years | |
| Thomas Mika | M | 72 | 9 years | |
| Aurora Cassirer | F | 72 | 2 years | |
| Brian W. Clymer | M | 77 |
Independent College Fund of New Jersey
| - |
| Julien Benitah | M | 41 | 2 years | |
| Rachel Bitan | F | 37 | 2 years | |
| Fashek Christopher | M | 74 | 8 years | |
| Maria Schroeder | F | 65 | 2 years | |
| James Lasry | M | 55 | 2 years | |
| Reid Brockmeier | M | - |
Independent College Fund of New Jersey
| - |
| Jamaleddine Mustapha | M | 62 | 2 years | |
| Mustapha Ghazali | M | 52 | 2 years | |
| Patrick Migliaccio | M | 50 |
Independent College Fund of New Jersey
| - |
| Lindsey Harrison | F | - | 3 years | |
| Itai Levinson | M | - | 6 years | |
| Saâd Bendidi | M | 65 | 2 years | |
| David M. Daly | M | - |
Independent College Fund of New Jersey
| - |
| Douglas G. Swenson | M | - |
Independent College Fund of New Jersey
| - |
| Frank D'Amelio | M | 66 |
Independent College Fund of New Jersey
| - |
| Kevin Cummings | M | 68 |
Independent College Fund of New Jersey
| - |
| Glenn C. Lockwood | M | 62 |
Independent College Fund of New Jersey
| - |
| Oury Marciano | M | 39 | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Samuel Backenroth | M | 39 |
Ohr Pharmaceutical, Inc.
 Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 9 years |
| Jason Scott Slakter | M | 66 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 5 years |
| William Stern | M | 82 | 3 years | |
| Orin Hirschman | M | 54 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 10 years |
| June Almenoff | M | 67 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 6 years |
| Thomas M. Riedhammer | M | 76 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 6 years |
| James Cardwell | M | 64 | 1 years | |
| Jona Zumeris | M | 73 | 15 years | |
| Claude Benitah | M | 74 | 2 years | |
| John M. Horne | M | 56 | - | |
| Amir Rippel | M | - | 10 years | |
| Avner Ingerman | M | 60 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 29 | 74.36% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Michael Ferguson
- Personal Network
